Bente Magny Bergersen
Position:
Phone:
Email:
 

Author network for Bente Magny Bergersen by COREMINE medical


Publications 2011

Brandsaeter BJ, Pillgram M, Berild D, Kjekshus H, Kran AM, Bergersen BM (2011)
Hospitalised patients with suspected 2009 H1N1 influenza A in a hospital in Norway, July - December 2009
BMC Infect Dis, 11, 75
PubMed 21435254

Publications 2009

Skeie L, Bugge H, Negaard A, Bergersen BM (2009)
Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study
HIV Med, 11 (3), 170-7
PubMed 19780861

Publications 2006

Bergersen BM (2006)
Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy
Drugs, 66 (15), 1971-87
PubMed 17100407

Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K (2006)
Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls
Scand J Infect Dis, 38 (8), 682-9
PubMed 16857615

Publications 2005

Bergersen BM, Sandvik L, Ellingsen I, Bruun JN (2005)
Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive
HIV Med, 6 (4), 260-7
PubMed 16011531

Bergersen BM, Tonstad S, Sandvik L, Bruun JN (2005)
Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients
Int J STD AIDS, 16 (5), 365-9
PubMed 15949067

Publications 2004

Bergersen BM, Sandvik L, Bruun JN (2004)
Body composition changes in 308 Norwegian HIV-positive patients
Scand J Infect Dis, 36 (3), 186-91
PubMed 15119363

Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004)
Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects
Eur J Clin Microbiol Infect Dis, 23 (8), 625-30
PubMed 15322938

Publications 2003

Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN (2003)
Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-nave and HIV-negative controls: results from a Norwegian study of 721 patients
Eur J Clin Microbiol Infect Dis, 22 (12), 731-6
PubMed 14610658